Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
5% Minoxidil · 1 trial · 1 indication
Number of hairs in the area being examined as measured by macrophotography.
| Arm | Type | Description |
|---|---|---|
| 5% MTF | EXPERIMENTAL | 5% Minoxidil Topical Foam |
| 2% MTS | ACTIVE_COMPARATOR | 2% Minoxidil Topical Solution |
| Name | Type | Description |
|---|---|---|
| 5% Minoxidil | DRUG | half a cap (equivalent to 1g) 5% Minoxidil Topical Foam applied to the scalp once daily, every day, for 52 weeks |
| 2% Minoxidil | DRUG | one ml of 2% Minoxidil Topical Solution applied to the scalp two times a day, every day, for 52 weeks |
Inclusion Criteria: * females, age 18 or older in general good health * exhibits female pattern hair loss * signs and dates an informed consent document * agrees to use an adequate method of birth control; if of childbearing potential * shows a negative urine pregnancy test at Screening Visit * is ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 6 | PHASE3 | Ritlecitinib higher dose |
| Veradermics, Incorporated | MANE | 4 | PHASE3 | VDPHL01 |
| AbbVie, Inc. | ABBV | 3 | PHASE3 | Upadacitinib |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Baricitinib |
| ICON Plc | ICLR | 1 | PHASE3 | Clascoterone 5%, Vehicle |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE3 | 5% minoxidil foam |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | bempikibart |
| Forte Biosciences Inc. | FBRX | 1 | PHASE1 | FB102 |
| Absci Corporation | ABSI | 1 | PHASE1 | ABS-201 Single Dose, ABS-201 Multiple Doses |
| HCW Biologics, Inc. | HCWB | 1 | PHASE1 | HCW9302, an IL-2 fusion protein |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | Dupilumab |
5% Minoxidil is a topical small molecule used for the treatment of alopecia, specifically female pattern hair loss. It is being developed by Johnson & Johnson and is currently in Phase 3 clinical development for this dermatological condition.
Johnson & Johnson (NYSE: JNJ) is the developer of 5% Minoxidil. The company is conducting clinical trials to evaluate the drug's safety and efficacy for the treatment of alopecia in women.
5% Minoxidil is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed, involving 322 female participants with female pattern hair loss.
5% Minoxidil has one completed Phase 3 clinical trial, NCT01145625, titled 'Clinical Trial in Females With Female Pattern Hair Loss.' The trial enrolled 322 female participants aged 18 years and older with alopecia, conducted in the United States, Canada, France, Germany, and the United Kingdom.
5% Minoxidil is a specific concentration of the active ingredient minoxidil. It is being studied as a treatment for female pattern hair loss, and the 5% formulation is the focus of the ongoing clinical development program.